Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Day One Biopharmaceuticals ( (DAWN) ) has issued an announcement.
On November 12, 2025, Day One Biopharmaceuticals announced a merger agreement to acquire Mersana Therapeutics, aiming to expand its oncology portfolio with Mersana’s novel ADC, emiltatug ledadotin (Emi-Le), which shows promise in treating adenoid cystic carcinoma type-1. The acquisition, valued at up to $285 million, is expected to close by January 2026, subject to regulatory approvals. This strategic move is anticipated to enhance Day One’s market position by leveraging its existing capabilities to develop and potentially commercialize Emi-Le, addressing unmet needs in cancer treatment.
The most recent analyst rating on (DAWN) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
Spark’s Take on DAWN Stock
According to Spark, TipRanks’ AI Analyst, DAWN is a Neutral.
Day One Biopharmaceuticals shows strong growth potential, particularly with the success of OJEMDA and a solid cash position. However, consistent net losses, negative technical indicators, and a challenging valuation due to ongoing losses present significant risks. The strong momentum from recent earnings highlights provides some optimism, balancing out the weaker financial and technical aspects.
To see Spark’s full report on DAWN stock, click here.
More about Day One Biopharmaceuticals
Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company based in Brisbane, California, focused on developing and commercializing targeted therapies for life-threatening diseases, particularly in pediatric cancer. Its pipeline includes tovorafenib (OJEMDA™) and DAY301. Mersana Therapeutics is a clinical-stage biopharmaceutical company specializing in novel antibody drug conjugates (ADCs) with platforms like Dolasynthen and Immunosynthen, targeting various cancers.
Average Trading Volume: 1,653,670
Technical Sentiment Signal: Buy
Current Market Cap: $1.06B
See more insights into DAWN stock on TipRanks’ Stock Analysis page.